Developing a pipeline of novel drugs targeting synthetic lethal interactions in DNA damage response pathways and tumor suppressor loss-of-function.

Creating diagnostic tools to identify cancer patients who would benefit from specific synthetic lethality-based treatments, including a diagnostic for ALT positive cancers.